Abstract. Peroxisome proliferator-activated receptor Á (PPARÁ) gene is a nuclear receptor that is involved in thyroid tumourigenesis. Recently, our group has shown that follicular carcinomas underexpressing PPARÁ protein are more prone to develop distant metastases, to invade locally, to present poorly differentiated areas and to persist after surgery. Aneuploidy is also observed in some thyroid tumours, particularly in the more advanced cases. The aim of the present study was to investigate the association of PPARÁ expression with the degree of differentiation and ploidy status of benign and malignant thyroid neoplasias. DNA cytometric studies, ploidy and S-phase fraction (SPF) determination, and quantitative RT-PCR analysis of molecular markers specific for thyroid follicular cells, namely Tg (thyroglobulin), TSHR (TSH receptor) and NIS (Na + /I -symporter) were compared between thyroid lesions with positive or negative PPARÁ protein expression. We observed that PPARÁ-negative tissues expressed lower levels of Tg mRNA [4.66x10 6 a.u. (arbitrary units) ± 1.49x10 6 ], and were more frequently aneuploid (36%), and presented higher SPF (3.1%±0.4) than PPARÁ-positive samples (Tg mRNA = 2.54x10 7 a.u. ± 9.72x10 6 , P=0.0006; aneuploidy=8%, P=0.0031; SPF=2.2%±0.2, P=0.0430). A similar trend was also observed for TSHR and NIS mRNA, although not reaching statistical significance. This study showed that underexpression of PPARÁ is associated with poor tumour differentiation, aneuploidy and higher cell proliferative activity. Therapies designed to modulate expression of PPARÁ may have an impact on the growth of thyroid neoplasias.
Introduction
The molecular genetics underlying thyroid carcinogenesis is not fully understood. Recently, rearrangements between PAX8 and PPARÁ (peroxisome proliferator-activated receptor Á) genes were associated with follicular thyroid carcinomas (FTCs) and adenomas (FTAs) (1) (2) (3) . PPARÁ is a nuclear receptor that participates in a wide range of cellular processes, such as adipocyte differentiation, lipid storage, insulin sensitization (4-6), cell cycle control, inflammation, atherosclerosis, apoptosis and carcinogenesis (7) . PPARÁ is activated by natural ligands (e.g., prostaglandin J2 and fatty acids derivatives) or by synthetic ligands (thiazolidinediones). These ligands induce apoptosis and exert anti-proliferative effects on several carcinoma cell lines and inhibit the growth of thyroid carcinoma cells in vivo (8) (9) (10) (11) . In different types of cancer, several studies have shown that, compared to their normal counterparts, tumours can present either overexpression (12, 13) , underexpression (14) or similar expression of PPARÁ (15) . Studies in human colon carcinomas, with monoallelic PPARÁ mutations, indicated that colon cancer is associated with loss-of-function mutations in PPARÁ (16) . In addition, PAX8PPARÁ fusion protein, resulting from the t(2;3)(q13;p25) translocation between PAX8 and PPARÁ genes, is present in a significant proportion of thyroid follicular tumours (1) .
Aneuploidy is one of the most frequent genetic abnormalities found in cancer. It results from full or partial aneusomies in which the copy number of entire chromosomes or chromosomal subregions is altered. Aneuploidy per se has been proposed to be an early and genetically destabilizing force in cancer development (17) , but the molecular mechanisms underlying aneuploidy are poorly understood. In thyroid lesions, aneuploidy is mostly found in poorly-differentiated thyroid carcinomas (PDTCs), is rare in papillary thyroid carcinomas (PTCs), being observed in a range of 10-57% of follicular tumours (18) , and in 10-22% of nodular hyperplasias (NHs) (19) (20) (21) .
In a previous study (22) , we demonstrated that follicular carcinomas that do not express PPARÁ protein by immunohistochemistry (IHC) are more prone to develop distant metastases, to invade locally, to present poorly differentiated areas and to persist after surgery. These results suggest an association between underexpression of PPARÁ and a less differentiated phenotype. Aiming to investigate this hypothesis, we determined the ploidy status, S-phase fraction (SPF) and the mRNA expression of molecular markers of thyroid follicular cells [Tg (thyroglobulin), TSHR (TSH receptor) and NIS (Na + /I -symporter)], by quantitative RT-PCR (QRT-PCR), in benign and malignant thyroid tissues with positive or negative PPARÁ staining.
Materials and methods
Materials. In a previous study by our group (22) , PPARÁ protein was detected by IHC in 77% of normal thyroid tissues (NTs), 71% of NHs (P>0.05, vs. NT), 62% of FTAs (P>0.05, vs. NT), 53% of FTCs (P=0.03, vs. NT) and 49% of PTCs (P=0.01, vs. NT). All PDTCs/ATC were negative (P<0.0001, vs. normal thyroid tissue). Positive staining was usually faint or moderate (in tissues negative for the PAX8/ PPARÁ rearrangement). From this published series, we selected cases (n=95), from which frozen samples were available, for RNA extraction and quantitative analysis of thyroid specific transcripts. These cases were: 10 NHs, 29 FTAs, 9 FTCs, 37 PTCs (15 classic, 14 follicular, 3 oxyphilic, 3 tall cells and 2 cribiform), 9 PDTCs and 1 anaplastic thyroid carcinoma (ATC). The material was retrieved from the files of the Portuguese Institute of Oncology Francisco Gentil, Lisboa, and institutional ethics guidelines were strictly followed. Samples were immediately frozen at time of surgery to subsequent RNA extractions and DNA flow cytometric analysis, and were also embedded in paraffin for immunohistochemistry. Haematoxylin-and eosin-stained sections were evaluated histologically by pathologists to classify the tumours according to the 2004 World Health Organization Classification of Tumours of Endocrine Organs.
RNA extraction and cDNA synthesis. Total RNA was isolated from frozen tissues by TRIzol reagent (Invitrogen, Paisley, UK), according to the manufacturer's protocol. RNA was quantified by UV spectrophotometry (optical density measured at 260 nm). Complementary DNA (cDNA) was synthesized from 1 or 2 μg [for quantitative real-time PCR (QRT-PCR)] of total RNA at 37˚C for 90 min, using oligo(dT) primers (Invitrogen) and reverse transcriptase (Superscript II, Invitrogen).
Detection of PAX8PPARÁ fusion gene. PAX8PPARÁ fusion gene was analysed in the entire series by RT-PCR (n=80) or FISH (n=4), and the remaining cases (n=11) by both techniques, as described previously (2, 22) . All the samples were negative for the PAX8PPARÁ fusion gene. This was an important criterion used for sampling selection, since the presence of the PAX8PPARÁ fusion protein increases the expression of wild-type PPARÁ protein (anti-PPARÁ antibody used in this study recognizes PPARÁ regions common to both PAX8PPARÁ fusion protein and to wild-type PPARÁ protein).
QRT-PCR.
The mRNA expression levels of Tg, NIS and TSHR were quantified using TaqMan probes for Tg and NIS analysis and SYBR Green dye for TSHR analysis, on an ABI PRISM 7900 HT Sequence Detection Systems (Applied Biosystems, Foster City, CA, USA). To analyze the mRNA expression levels of Tg and NIS by TaqMan probes, specific primers and the probes were selected from the Assay-ondemand products [P/N 4331182; Hs00794359_m1 (Tg), Hs00166567_m1 (NIS); Applied Biosystems]. In order to normalize the differences in the amount of total cDNA used in each reaction, we performed the amplification of GAPDH cDNA as endogenous control (Pre-Developed TaqMan Assay Reagents; P/N 4326317E; Applied Biosystems). Gene expression assays have a FAM (Tg and NIS) or a VIC (GAPDH) reporter dye at 5'-end of the TaqMan MGB probe, and a non-fluorescent quencher at the 3'-end of the probe. To analyse the mRNA expression level of TSHR by SYBR Green dye, we used the following primers: TSHR F (5'-GAA CTGATAGCAAGAAACACCTGG-3') and TSHR R (5'-GTA TCCTGGAACTTGGACTTTT-3') for TSHR gene and PGK F (5'-CAGTTTGGAGCTCCTGGAAG-3') and PGK R (5'-TGC AAATCCAGGGTGCAGTG-3') for PGK-1 gene (23) .
cDNA of each sample was synthesized from 2 μg of RNA, as described above. Quantitative RT-PCR was performed in a total reaction volume of 25 μl containing 1X TaqMan Universal PCR Master Mix (P/N 4304437; Applied Biosystems), 1X Assays-on-demand Gene Expression Assay Mix and 2 μl of cDNA diluted in RNase-free water, or 1X SYBR Green PCR Master Mix (P/N 4309155; Applied Biosystems), 10 pmol of each primer and 2 μl of cDNA diluted in RNase-free water. All reactions were performed in a 96-well reaction plate (MicroAmp Optical 96-Well Reaction Plate, Applied Biosystems). Samples were heated for 2 min at 50˚C, followed by 10 min at 95˚C and amplified for 50 cycles of 15 sec at 95˚C and 1 min at 60˚C. SYBR Green assays were followed by a dissociation curve analysis. cDNA from Nthy-ori 3-1 cell line (SV40 large-T-antigen immortalized normal human differentiated thyroid cellsEuropean Collection of Cell Culture, Wiltshire, UK) was serially diluted in dH 2 O and amplified in parallel to establish a standard curve for relative quantification. Nthy-ori cell cDNA was also used as calibrator for determining the relative expression of Tg, NIS and TSHR genes. For each sample, the amount of target RNA was normalised to the standard curve, then normalised to the endogenous control RNA expression and then to the calibrator. All quantitative real-time RT-PCR experiments, including a control with no template, were performed in triplicate.
The mRNA expression levels for Tg were analysed in 31 samples (20 FTAs DNA flow cytometry. Flow cytometric analysis was performed in representative tumour tissue frozen at -80˚C at time of surgery. Tissue samples were disaggregated mechanically using sterile surgery blades in phosphate-buffered saline (PBS) in a Petri plaque. Then, the cell suspension was washed twice and cells were counted in a Bürker's counting chamber. To perform the DNA-specific staining (24) , cells were treated with a solution of ribonuclease 1 mg/ml (Sigma-Aldrich, St. Louis, USA) in PBS, for digestion of double-stranded RNA, and a non-ionic detergent Nonidet P40 0.05% (SigmaAldrich), for cell lysis. Nuclei were stained with propidium iodide (Sigma), 50 μg/ml in Tris-MgCl 2 , for 1 h at 4˚C in the dark. After filtration with a 55-μm nylon mesh, the stained cell nuclei were analysed on an Epics Profile II (Flow cytometer, Coulter Electronics, Hialeah, FL, USA) equipped with a 488-nm argon-ion laser. The instrument was aligned daily and considered calibrated when the coefficients of variation (CVs) of standard fluorescent microspheres were below 2% (DNA-Check, Coulter). At least 20000 nuclei were acquired for each case and the results were recorded on a single parameter 256 channel fluorescence histogram.
Cell cycle analysis of DNA histograms was performed with the Multicycle program (Phoenix Flow Systems, San Diego, CA, USA), based on the mathematical method described by Dean and Jett (25) Statistical analysis. The comparison of Tg, TSHR and NIS mRNA expression levels between PPARÁ protein negative and positive tissues was performed by the Mann-Whitney test. DNA ploidy and SPF were analysed in the different thyroid histotypes with the ¯2 test, and one-way ANOVA test (with the Dunnett's Multiple Comparison test), respectively. To correlate SPF with ploidy status and PPARÁ protein expression we used the unpaired t-test (two-tailed). To correlate the PPARÁ protein expression with ploidy, we used the Fisher's exact test (two-tailed). Non-parametric tests were used when the data were not normally distributed. P-values ≤0.05 were considered significant. Statistical analysis was performed using GraphPad Prism statistical software (San Diego, CA, USA). All graphs with error bars indicate means ± standard error of the mean (SEM).
Results

Correlation between the expression of the PPARÁ protein and the expression of Tg, TSHR and NIS mRNAs. The mean
Tg mRNA expression level was lower in PPARÁ-negative [4.66x10 6 a.u. (arbitrary units) ± 1.49x10 6 ; n=17] than in PPARÁ-positive cases (2.54x10 7 a.u. ± 9.72x10 6 ; n=14; P=0.0006) (Fig. 1A) . This difference in Tg mRNA expression was also statistically significant within the group of FTAs (PPARÁ-, 4.06x10 6 a.u. ± 1.58x10 6 ; n=10 vs. PPARÁ+, 3.24x10 7 a.u. ± 1.32x10 7 ; n=10; P=0.0021). Although not (Fig. 1B and C (Fig. 2) .
Correlation between PPARÁ protein expression and ploidy.
The correlation between PPARÁ protein expression and ploidy is summarised in Table III. In the whole series, PPARÁ-negative thyroid lesions were more frequently aneuploid (21 of 58; 36%) than PPARÁ-positive lesions (3 of 37; 8%) (P=0.0031). After excluding the PDTC/ATC subgroup, which presented aneuploidy in the vast majority of the cases, the difference was still statistically significant: 14 of 48 (29%) in PPARÁ-negative vs. 3 of 37 (8%) in PPARÁ-positive cases (P=0.0268). If nodular hyperplasias were excluded from the analysis the frequency of aneuploidy was still higher in PPARÁ-negative than in PPARÁ-positive tumours: 19 of 52 (37%) in PPARÁ-negative vs. 3 of 33 (9%) in PPARÁ-positive (P=0.0052).
Correlation between PPARÁ protein expression and SPF.
PPARÁ-negative lesions presented higher SPF than PPARÁ-positive cases (PPARÁ-, 3.1%±0.4; n=40 vs. PPARÁ+, 2.2%±0.2; n=31; P=0.0430) (Fig. 3) . This finding remained statistically significant considering only the neoplastic tissues (FTAs, FTCs, PTCs and PDTC) (PPARÁ-, 3.2%±0.4; n=36 vs. PPARÁ+, 2.2%±0.2; n=27; P=0.0449). However, it lost Table I . Ploidy analysis in benign and malignant thyroid lesions.
.0039 (frequency of aneuploidy vs histotype); n, number of samples.
- Table II . S-phase cell fraction in benign and malignant thyroid lesions.
One-way ANOVA test, P<0.0001. a Dunnett's Multiple Comparison test, each histotype vs. PDTCs; n, number of samples; n.s., nonsignificant. significance when the PDTCs, which presented the highest SPF values, were removed (PPARÁ-, 2.5%±0.3; n=32 vs. PPARÁ+, 2.2%±0.2; n=31; P>0.05).
Discussion
In a previous study (22) , we analysed the expression of PPARÁ in several types of thyroid lesions and observed that clinically aggressive tumours had lower PPARÁ protein expression than less aggressive carcinomas. Based on this finding, we hypothesized that low levels of PPARÁ expression might be correlated with lower expression of thyroid specific genes such as Tg, TSHR and NIS. Furthermore, since aneuploidy is more prevalent in poorly-differentiated thyroid carcinomas (26) (27) (28) , we also investigated the correlation of PPARÁ expression with the ploidy status and the proliferative activity of thyroid lesions.
When all thyroid histotypes were grouped together, the levels of Tg mRNA were significantly lower in PPARÁ negative lesions than in cases staining for PPARÁ. The same was observed in the group of FTAs, which are benign tumours. Although not reaching statistical significance, the levels of TSHR and NIS mRNA were also lower in PPARÁ-negative than in PPARÁ-positive cases. These results suggest that loss of PPARÁ is related to a lower differentiation of thyroid follicular cells. This conforms well with the inhibition of cell proliferation and induction of apoptosis or cell differentiation which is observed in several types of cancers (8) (9) (10) (11) 15, (29) (30) (31) (32) (33) (34) (35) , following treatment with specific PPARÁ agonists. It is well known that the activation of PPARÁ suppresses the transcriptional activity of the E2F/DP complex (36) . E2F is a transcription factor that regulates the expression of genes involved in entry into S phase and in DNA synthesis (37, 38) and DP is an E2F-related protein that stabilizes E2F. According to Altiok et al (39) PPARÁ activation leads to a loss of binding of E2F/DP to DNA, due to an increase in phosphorylation of this complex. The action of PPARÁ on E2F/DP function may also be important at the level of cell differentiation. There are differentiation-promoting agents that cause a decrease in the DNA-binding activity of E2F/DP complex, during the differentiation of several types of cells (40) (41) (42) (43) .
In general, aneuploid thyroid lesions presented higher SPF than diploid cases (5.7±0.8 vs. 2.2±0.1; P<0.0001) (Fig. 2) . Higher proliferative activity has been found in thyroid carcinomas (FTCs and mixed follicular/papillary thyroid carcinomas) as compared to benign lesions (FTAs) and normal thyroid (44) . Konarska et al (45) observed similar findings in three different thyroid tissues [colloid goiters, diploids (8.6%) vs. aneuploids (13.7%); parenchimatous goiters, diploids (3.7%) vs. aneuploids (6.7%); adenomas, diploids (8.4%) vs. aneuploids (10.2%)]. However, our SPF data should be considered with caution, since there is a lack of correlation with PPARÁ expression when the PDTC subgroup, which showed the highest SPF values, was excluded from the SPF analysis.
In our study, the PPARÁ-negative cases were more frequently aneuploid (Table III) and presented higher SPF (Fig. 3) than cases expressing PPARÁ. The molecular mechanism linking PPARÁ to ploidy of thyroid neoplasias remains largely unknown. However, the loss of PPARÁ expression may favour chromosomal instability because PPARÁ activation induces a block in the G 1 -S transition by inhibiting RB (retinoblastoma) phosphorylation and by the attenuation of mitogen-induced p27 degradation (46) (47) (48) .
An alternative hypothesis is that chromosomal instability could be the driving force that contributes to underexpression of PPARÁ and loss of expression of the thyroid-specific genes during the malignant progression of thyroid tumours.
In sum, our results showed that there is an association between underexpression of PPARÁ, aneuploidy, and lower cell differentiation of thyroid tumours. Therapies designed to modulate expression of PPARÁ may have an impact in tumour growth of thyroid neoplasias. PPARÁ  PPARÁ  immunohistochemistry  immunohistochemistry  Negative  Positive  ------------------------- -------------------------Histotype (n) Diploid (%) Aneuploid (%) Histotype (n) Diploid (%) Aneuploid (%) P-value a -----------------------------------------------------------------------------------------------------NH (n=6) ----------------------------------------------------------------------------------------------------- a Fisher's exact test (PPARÁ immunostaining vs. ploidy); n, number of samples; n.s., non-significant.
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